Retirement Systems of Alabama Reduces Holdings in Repligen Co. (NASDAQ:RGEN)

Retirement Systems of Alabama lowered its position in Repligen Co. (NASDAQ:RGEN) by 1.3% during the third quarter, HoldingsChannel reports. The firm owned 63,272 shares of the biotechnology company’s stock after selling 865 shares during the period. Retirement Systems of Alabama’s holdings in Repligen were worth $9,416,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Champlain Investment Partners LLC raised its position in shares of Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after buying an additional 850,345 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Repligen by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock worth $172,749,000 after purchasing an additional 237,884 shares in the last quarter. Conestoga Capital Advisors LLC lifted its stake in Repligen by 26.7% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after purchasing an additional 199,322 shares in the last quarter. Thrivent Financial for Lutherans grew its position in shares of Repligen by 6.1% in the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock valued at $95,037,000 after purchasing an additional 36,773 shares in the last quarter. Finally, DF Dent & Co. Inc. increased its holdings in shares of Repligen by 31.0% in the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after purchasing an additional 139,615 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

RGEN has been the topic of a number of recent research reports. Wolfe Research initiated coverage on Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating on the stock. Wells Fargo & Company began coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price target on the stock. Royal Bank of Canada restated an “outperform” rating and set a $205.00 price objective on shares of Repligen in a research report on Thursday, September 26th. Finally, StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, November 22nd. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Price Performance

Repligen stock opened at $160.92 on Tuesday. The company’s 50 day simple moving average is $142.66 and its 200-day simple moving average is $141.59. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $211.13. The company has a market capitalization of $9.02 billion, a price-to-earnings ratio of -434.92, a price-to-earnings-growth ratio of 4.64 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same quarter in the previous year, the company earned $0.23 earnings per share. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. As a group, equities research analysts expect that Repligen Co. will post 1.54 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.